Home › Companies › Aclaris Therapeutics, Inc. › 2025-2026

Aclaris Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Aclaris Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

4Ballot items
139Asset managers
624Fund votes
June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 4 items on Aclaris Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 2 approved · 2 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2025-2026

Explore Aclaris Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Aclaris Therapeutics, Inc.

These tallies are Aclaris Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Aclaris Therapeutics, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Anand Mehra, M.D.	83,063,569	--	--	10,075,624	19,360,478	89%	Not verified	—
Elect Director: Maxine Gowen, Ph.D.	84,209,108	--	--	8,930,085	19,360,478	90%	Not verified	—
2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement	83,370,124	9,734,691	34,378	--	19,360,478	90%	Approved	—
3. The selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026	112,322,811	159,714	17,146	--	--	99.8%	Approved	—

Source: Aclaris Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Aclaris Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 139 asset managers that disclosed a Aclaris Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Anand Mehra, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 83,063,569WITHHELD: 10,075,624

Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Directors: Anand Mehra, M.D.

Aclaris Therapeutics, Inc.’s own tally for this item (“Elect Director: Anand Mehra, M.D.”): 83,063,569 for, 10,075,624 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 13,870,850 for, 1,148,790 withheld, 47,632 abstained.

FOR

FOR: 13,870,850ABSTAIN: 47,632WITHHOLD: 1,148,790

Largest asset managers voting on “Election of Directors: Anand Mehra, M.D.” at Aclaris Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	5,922,577	16	7,626	For
BlackRock	4,271,236	0	0	For
Fidelity	2,080,153	0	144,393	Mixed
JPMorgan	280,173	0	0	For
Charles Schwab	260,963	0	0	For
BRIDGEWAY FUNDS INC	0	0	223,739	Withhold
Equitable	151,244	0	7,600	For
QUANTITATIVE MASTER SERIES LLC	157,263	0	0	For
Russell Investments	140,937	0	0	For
Dimensional	0	0	140,259	Withhold
Goldman Sachs	119,875	0	0	For
American Century	0	0	118,702	Withhold
Brighthouse	75,268	0	38,982	Mixed
AIG/SunAmerica	0	0	102,584	Withhold
ALPS ETF Trust	0	0	98,175	Withhold
TIAA	0	0	90,480	Withhold
Invesco	80,559	0	0	For
Lincoln Financial	67,000	0	0	For
Pacific Life	35,716	0	19,779	Mixed
Global X	43,454	0	0	For
Bridge Builder Trust	42,353	0	0	For
Northern Trust	0	0	42,210	Withhold
AQR	0	0	35,656	Withhold
State Street	33,633	0	0	For
FORUM FUNDS II	28,431	0	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

2. Elect Director: Maxine Gowen, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%

FOR: 84,209,108WITHHELD: 8,930,085

Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Directors: Maxine Gowen, Ph.D.

Aclaris Therapeutics, Inc.’s own tally for this item (“Elect Director: Maxine Gowen, Ph.D.”): 84,209,108 for, 8,930,085 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 13,931,312 for, 1,088,329 withheld, 47,631 abstained.

FOR

FOR: 13,931,312ABSTAIN: 47,631WITHHOLD: 1,088,329

Largest asset managers voting on “Election of Directors: Maxine Gowen, Ph.D.” at Aclaris Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	5,922,578	15	7,626	For
BlackRock	4,271,236	0	0	For
Fidelity	2,080,153	0	144,393	Mixed
JPMorgan	280,173	0	0	For
Charles Schwab	260,963	0	0	For
BRIDGEWAY FUNDS INC	0	0	223,739	Withhold
Equitable	158,844	0	0	For
QUANTITATIVE MASTER SERIES LLC	157,263	0	0	For
Russell Investments	140,937	0	0	For
Dimensional	0	0	140,259	Withhold
Goldman Sachs	119,875	0	0	For
American Century	0	0	118,702	Withhold
Brighthouse	75,268	0	38,982	Mixed
AIG/SunAmerica	0	0	102,584	Withhold
ALPS ETF Trust	0	0	98,175	Withhold
TIAA	0	0	90,480	Withhold
Invesco	80,559	0	0	For
Lincoln Financial	67,000	0	0	For
Pacific Life	35,716	0	19,779	Mixed
Global X	43,454	0	0	For
Bridge Builder Trust	42,353	0	0	For
Northern Trust	42,210	0	0	For
AQR	0	0	35,656	Withhold
State Street	33,633	0	0	For
FORUM FUNDS II	28,431	0	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

3. 2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%

FOR: 83,370,124AGAINST: 9,734,691

Details: description as filed, official tally, votes by 139 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.

Aclaris Therapeutics, Inc.’s own tally for this item (“2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 83,370,124 for, 9,734,691 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 47 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at Aclaris Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,926,550	3,669	0	For
BlackRock	4,271,236	0	0	For
Fidelity	2,080,153	144,393	0	Mixed
JPMorgan	0	280,173	0	Against
Charles Schwab	260,963	0	0	For
BRIDGEWAY FUNDS INC	0	223,739	0	Against
Equitable	151,244	7,600	0	For
QUANTITATIVE MASTER SERIES LLC	157,263	0	0	For
Russell Investments	140,937	0	0	For
Dimensional	0	140,259	0	Against
Goldman Sachs	119,875	0	0	For
American Century	118,702	0	0	For
Brighthouse	0	104,911	9,339	Mixed
AIG/SunAmerica	0	102,584	0	Against
ALPS ETF Trust	0	98,175	0	Against
TIAA	90,480	0	0	For
Invesco	0	80,559	0	Against
Lincoln Financial	67,000	0	0	For
Pacific Life	35,716	19,779	0	Mixed
Global X	43,454	0	0	For
Bridge Builder Trust	42,353	0	0	For
Northern Trust	42,210	0	0	For
AQR	0	35,656	0	Against
State Street	33,633	0	0	For
FORUM FUNDS II	28,431	0	0	For

Fund voting reports, all 47 managers: 13,690,780 for, 1,367,153 against, 9,339 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 108 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at Aclaris Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Deep Track Capital, LP	9,345,000	0	For
RA CAPITAL MANAGEMENT, L.P.	8,316,239	0	For
Vivo Capital, LLC	6,666,666	0	For
Frazier Life Sciences Management, L.P.	4,925,374	0	For
Rock Springs Capital Management LP	4,472,650	0	For
Decheng Capital LLC	4,041,736	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	3,871,000	Against
BlackRock	2,675,170	56,214	For
GEODE CAPITAL MANAGEMENT, LLC	2,426,094	0	For
Kalehua Capital Management LLC	1,832,365	0	For
State Street	1,779,239	25,061	For
Woodline Partners LP	1,271,329	0	For
ACADIAN ASSET MANAGEMENT LLC	0	1,035,652	Against
Aldebaran Capital, LLC	947,551	0	For
Citadel	800,367	0	For
Vanguard	697,652	4,123	For
Northern Trust	642,461	30,689	For
BALYASNY ASSET MANAGEMENT L.P.	626,985	0	For
BRAIDWELL LP	587,399	0	For
Renaissance	0	439,517	Against
Aisling Capital Management LP	434,455	0	For
T. Rowe Price	0	407,874	Against
MPM BioImpact LLC	391,918	0	For
SUPERSTRING CAPITAL MANAGEMENT LP	366,490	0	For
MARSHALL WACE, LLP	333,531	0	For

Institutional-manager reports, all 108 managers: 55,340,117 for, 8,563,869 against, 351 not voted. Showing the 25 largest; see all in the interactive database.

4. 3. The selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%

FOR: 112,322,811AGAINST: 159,714

Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2026.

Aclaris Therapeutics, Inc.’s own tally for this item (“3. The selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 112,322,811 for, 159,714 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 15,057,933 for, 9,339 abstained.

FOR

FOR: 15,057,933ABSTAIN: 9,339

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the ” at Aclaris Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	5,930,219	0	For
BlackRock	4,271,236	0	For
Fidelity	2,224,546	0	For
JPMorgan	280,173	0	For
Charles Schwab	260,963	0	For
BRIDGEWAY FUNDS INC	223,739	0	For
Equitable	158,844	0	For
QUANTITATIVE MASTER SERIES LLC	157,263	0	For
Russell Investments	140,937	0	For
Dimensional	140,259	0	For
Goldman Sachs	119,875	0	For
American Century	118,702	0	For
Brighthouse	104,911	9,339	Mixed
AIG/SunAmerica	102,584	0	For
ALPS ETF Trust	98,175	0	For
TIAA	90,480	0	For
Invesco	80,559	0	For
Lincoln Financial	67,000	0	For
Pacific Life	55,495	0	For
Global X	43,454	0	For
Bridge Builder Trust	42,353	0	For
Northern Trust	42,210	0	For
AQR	35,656	0	For
State Street	33,633	0	For
FORUM FUNDS II	28,431	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Largest Aclaris Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 139,663,680 shares outstanding at the time of that meeting.

Fund voting reports: top Aclaris Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	4.25%
2	BlackRock	3.06%
3	Fidelity	1.59%
4	JPMorgan	0.20%
5	Charles Schwab	0.19%
6	BRIDGEWAY FUNDS INC	0.16%
7	Equitable	0.11%
8	QUANTITATIVE MASTER SERIES LLC	0.11%
9	Russell Investments	0.10%
10	Dimensional	0.10%

Institutional-manager reports: top Aclaris Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Deep Track Capital, LP	6.69%
2	RA CAPITAL MANAGEMENT, L.P.	5.95%
3	Vivo Capital, LLC	4.77%
4	Frazier Life Sciences Management, L.P.	3.53%
5	Rock Springs Capital Management LP	3.20%
6	Decheng Capital LLC	2.89%
7	ADAGE CAPITAL PARTNERS GP, L.L.C.	2.77%
8	BlackRock	1.96%
9	GEODE CAPITAL MANAGEMENT, LLC	1.74%
10	Kalehua Capital Management LLC	1.31%

Reported Aclaris Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Aclaris Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BML Investment Partners, L.P.	9.99%	13G
Biosion, Inc.	8.08%	13G
Frazier Life Sciences Public Fund, L.P.	5.64%	13G
BlackRock	5.30%	13F
Vanguard Group	4.66%	13F
Vivo Opportunity Fund Holdings, L.P.	4.27%	13G
Morgan Stanley	2.45%	13F
Citadel Advisors	2.02%	13F
Geode Capital	1.74%	13F
State Street	1.44%	13F

Percentages above are of 139,663,680 shares outstanding, as reported by Aclaris Therapeutics, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aclaris Therapeutics, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Aclaris Therapeutics, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 139 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 624 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — Aclaris Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Aclaris Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Aclaris Therapeutics, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.